A study of the combination of oxaliplatin, capecitabine, and trastuzumab and chemo-radiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastroesophageal junction cancer (TOXAG study).

Abali, HuseyinYalcin, SuayibOnal, CemDane, FaysalOksuzoglu, BernaOzdemir, NuriyeMertsoylu, HuseyinArtac, MehmetCamci, CelaletdinKarabulut, BulentBasal, Fatma BugdayciBudakoglu, BurcinSendur, Mehmet Ali NahitGoktas, BurceOzdener, FatihBaygul, Arzu2019-10-272019-10-2720180732-183X1527-7755https://doi.org/10.1200/JCO.2018.36.4_suppl.26https://hdl.handle.net/11454/30678Gastrointestinal Cancers Symposium -- JAN 18-20, 2018 -- San Francisco, CAen10.1200/JCO.2018.36.4_suppl.26info:eu-repo/semantics/closedAccessA study of the combination of oxaliplatin, capecitabine, and trastuzumab and chemo-radiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastroesophageal junction cancer (TOXAG study).Conference Object364WOS:000436174100026Q1